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Neurodegenerative diseases, such as Parkinson’s disease (PD), Alzheimer’s disease (AD),
and Dementia with Lewy bodies (DLB), display an accumulation of proteins including
α-synuclein aggregates in cortical and subcortical regions of the brain. PD is a complex,
progressive disease which involves damage of motor and cognitive brain regions, as
well as autonomic and sensory areas. Since α-synuclein is a neuronal cytosolic protein,
it is assumed that pathogenic changes induced by α-synuclein aggregates occur only
at the cytoplasmic level. However, recent studies have identified the presence of
extracellular α-synuclein, suggesting that the pathogenic action of this protein may
also occur in the extracellular milieu through an unknown mechanism. One of the
hypotheses is that extracellular α-synuclein aggregates or oligomers may directly disrupt
the neuronal membrane by the formation of a pore reminiscent to the ones formed by
β-amyloid aggregates. Here, we will review some evidence that support this mechanism,
analyzing the interactions of α-synuclein with components of the plasma membrane, the
formation of pore/perforated structures, and the implications on ionic dyshomeostasis.
Furthermore, we will also discuss how this mechanism can be integrated into a general
phenomenon that may explain the synaptotoxicity and neurotoxicity observed in different
neurodegenerative diseases.
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NEURODEGENERATIVE DISEASES AND α-SYNUCLEIN
Neurodegenerative diseases typically involve deposits of inclusion
bodies that contain abnormal aggregated proteins (Bossy-Wetzel
et al., 2004). Therefore, it has been suggested that protein aggre-
gation is a pathogenic process, characterized by multi-steps in
protein conformational changes (Ross and Poirier, 2004).
The homeostasis of proteins, or recently called Proteostasis,
refers to different cellular pathways that regulate protein synthe-
sis, folding, function, and degradation (Roth and Balch, 2011).
There is plenty of evidence indicating that the overall proteosta-
sis is impaired with aging, manifesting an increase in protein
oxidation along with changes that exacerbate the aggregation,
providing a partial explanation for several diseases known as
conformational diseases (Balch et al., 2008). Neurodegenerative
diseases are conformational diseases characterized by abnor-
mal protein deposition, which can be cytoplasmic, nuclear,
or extracellular (Bossy-Wetzel et al., 2004). Protein aggregates
called Amyloid are characterized by a β-sheet secondary struc-
ture presenting higher affinity to bind dyes like Congo red and
Thioflavin-T, higher resistance to proteolytic degradation, and a
fibrillar appearance under electron microscopy (Ross and Poirier,
2004).
Abbreviations: AD, Alzheimer’s disease; LBs, Lewy bodies; PD, Parkinson’s
disease.
α-Synuclein is an unstructured soluble protein that can assem-
ble into amyloid aggregates forming intracellular inclusion bodies
called Lewy bodies (LBs) present in Parkinson’s disease (PD),
Dementia with Lewy bodies (DLB), andMultiple System Atrophy
(MSA) (Spillantini et al., 1997, 1998; Tu et al., 1998). These
disorders are known as synucleinopathies. However, this neu-
ropathological feature is also commonly found in both sporadic
and familial cases of Alzheimer’s disease (AD). Therefore, α-
synuclein dysfunction might be a common factor in several
neurodegenerative diseases (Goedert, 2001).
LBs consist of eosinophilic and round cytoplasmic inclu-
sions that are particularly enriched in the substantia nigra in
PD (Braak et al., 2004), cortical brain areas in DLB (Kosaka,
1978), and amygdala in AD (Lippa et al., 1999). However, there
is wide evidence that indicates that small α-synuclein species (i.e.,
oligomers) are responsible for the synaptotoxicity, neurotoxicity,
and the final spread of this neurodegenerative disease through-
out the brain (Winner et al., 2011). Therefore, the formation of
α-synuclein inclusion bodies could be a protective mechanism
against the smaller species. Nevertheless, it is possible that both
soluble misfolded intermediates and amyloid-like fibril deposits
may be toxic, but perhaps by different cellular mechanisms. For
example, soluble oligomeric species in AD might affect synaptic
transmission (Parodi et al., 2010), whereas LBs are intracellular
space-occupying entities that may interfere with neuronal and
glial intercellular communication (Goedert, 2001).
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Here, we will review the progression pattern of PD and some
properties of α-synuclein oligomers, especially their association
to the membrane. Finally, we will propose that extracellular α-
synuclein is implicated in synaptotoxicity and neurotoxicity by
making the plasma membrane more permeable.
PARKINSON’S DISEASE
PD is a human motor control disorder and the second most com-
mon neurodegenerative disorder after AD (Goedert, 2001). It
affects 1–2% of the adult population over 65 years and is clinically
characterized by muscle rigidity, bradykinesia (slowness of move-
ment), and tremor at rest (Jankovic, 2008). Pathologically, PD
is characterized by loss of dopaminergic neurons in the substan-
tia nigra pars compacta (an important region of the basal ganglia
that regulates movement) (Goedert, 2001) and by the intracellular
accumulation of LBs in surviving neurons and Lewy neurites that
advance in a topographically predictable sequence (Braak et al.,
2004).
The etiology of PD is unknown, although older age and neu-
rotoxins are established risk factors (Marttila and Rinne, 1981;
Langston et al., 1983). Actually, there is much evidence suggest-
ing that α-synuclein aggregates participate in the pathogenesis of
the disease. First, intraneuronal LBs are a histological feature of
PD (Spillantini et al., 1997, 1998). Second, genetic analyses have
identified three mutations of α-synuclein associated to inherited
forms of PD (Polymeropoulos et al., 1997; Kruger et al., 1998;
Zarranz et al., 2004), where each of the mutant variants have been
shown to alter the oligomerization or fibrilization of the protein
(Conway et al., 2000). Finally, it was determined that duplica-
tion or triplication of the gene locus of α-synuclein results in an
increased expression of this protein, linked to a familial form of
PD (Singleton et al., 2003; Chartier-Harlin et al., 2004; Ibanez
et al., 2004). Overall, these findings suggest that the accumulation
of α-synuclein is a critical factor in PD.
PARKINSON’S PROGRESSION
PD is mainly described as a motor disease, but as the disease pro-
gresses important regions associated to autonomic, limbic, and
somatomotor functions become affected (Figure 1) (Braak et al.,
2004). Moreover, dementia, a non-motor symptom, is detected
in a large proportion of patients with PD over the course of
the disease; however, the time of onset and rate of the cognitive
decline is highly variable (Aarsland et al., 2007). Dementia with
LBs accounts for ∼30% of all age-related dementias, and up to
40% of AD cases exhibit α-synuclein pathology (Parkkinen et al.,
2003; Jellinger, 2004; Mikolaenko et al., 2005; Zaccai et al., 2005).
It is interesting to note that 20–40% of PD patients have cogni-
tive impairments at disease onset and that ∼80% of PD patients
eventually develop dementia (PDD) (Aarsland et al., 2007). In
some individuals, however, cognitive decline can develop in the
FIGURE 1 | Different stages of Parkinson’s disease. The scheme
shows the progression of PD in the human central nervous system.
α-Synuclein can assemble into amyloid aggregates forming Lewy
bodies (LBs) and Lewy neurites, beginning at specific brain regions
(dark colors) and progressing through different brain areas (light
colors), in a topographically predictable sequence (Braak et al., 2004).
The right arrow shows the progression of PD, indicating some of the
brain regions related to presymptomatic and symptomatic phases.
Dark colors indicate early stages of PD and light colors indicate late
stages of PD.
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presence of mild PD-related cortical pathology and, conversely,
widespread cortical lesions do not necessarily lead to cognitive
decline (Braak et al., 2005). The mechanisms leading to the
initiation and spread of α-synuclein pathology in PD are not
well understood and one possibility to answer this query is that
α-synuclein aggregates can progress to different brain areas in
a similar manner to the propagation of prion diseases (Aguzzi,
2009). Interestingly, spread of LBs from host tissues to long-
term fetal cell grafts in the brain of PD patients has been shown
(Kordower et al., 2008) and supported by other studies (Mendez
et al., 2005; Li et al., 2008). Therefore, it appears possible to
generate the formation of LB-like structures in healthy normal
neurons.
CELL BIOLOGY AND BIOCHEMISTRY OF α-SYNUCLEIN
LOCALIZATION
The synuclein protein family is expressed in three forms,
α-, β-, and γ-synuclein, which have multiple locations (Lavedan,
1998). Immunohistochemical studies have shown that α- and
β-synuclein are mainly found in nerve terminals, in close prox-
imity to synaptic vesicles in the central nervous system (Clayton
and George, 1999). In contrast, γ-synuclein seems to be present
throughout nerve cells in the peripheral nervous system (Clayton
and George, 1999). Regarding cellular localization, α-synuclein is
located in the cytoplasmic space, but recent studies have also iden-
tified the presence of extracellular α-synuclein (El-Agnaf et al.,
2003). An analysis of α-synuclein levels in the cerebrospinal
fluid (CSF) of patients clinically diagnosed with PD, progressive
supranuclear palsy (PSP), AD, and age matched controls have
shown that CSF α-synuclein oligomer levels are higher in the PD
group as compared with the other three groups (Tokuda et al.,
2010). This result indicates that α-synuclein is present in extra-
cellular brain fluids, but most importantly, α-synuclein oligomers
are enriched in the extracellular space in PD. In agreement with
this, a previous report described that α-synuclein is normally
released by neuronal cells and is present in human CSF and
peripheral plasma (El-Agnaf et al., 2003), indicating that some-
how α-synuclein may be released under physiological conditions.
Moreover, these results suggest that α-synuclein might be able to
act at both intra- and extracellular spaces and open the possibility
that extracellular α-synuclein oligomers diffuse from one cell to
another, which could explain in some way the progression of the
disease to other brain regions.
STRUCTURE
α-Synuclein has four isoforms composed by 98, 112, 126, and 140
amino acids, with the latter being the most abundant (Bisaglia
et al., 2009). Under a native soluble conformation, α-synuclein is
found as an unfolded protein without a stable tertiary structure
belonging to intrinsically unstructured proteins. It is recognized
that its conformation can change depending on several condi-
tions (Uversky and Fink, 2002). In fact, when α-synuclein is in the
presence of anionic micelles, the conformation of its N-terminal
region is predominantly α-helix (Ulmer and Bax, 2005). The
N-terminal domain of α-synuclein is almost entirely composed
of eleven complete amino acid repeats that contain the consen-
sus sequence, XXKTKEGVXXXX, spanning the first 89 residues of
the protein, where three mutations (A30P, E46K, and A53T) asso-
ciated with early development of PD are localized (Bisaglia et al.,
2009). This domain is remarkably similar to a domain present in
apolipoproteins, which is characterized by amphipathic α-helices
(Davidson et al., 1998). With respect to the central domain
of α-synuclein, it is highly amyloidogenic, rich in hydrophobic
amino acids (60–95) and responsible for the aggregation and
β-sheet formation (Bisaglia et al., 2009). β-Synuclein, on the other
hand, lacks this domain and therefore cannot aggregate, which
correlates well with studies that show that α-synuclein levels are
increased in pathogenic conditions while β-synuclein levels are
decreased (Rockenstein et al., 2001). This segment was identified
in the brain of patients with AD and called the “non amyloido-
genic component” (NAC) of senile plaques (Masliah et al., 1996).
Finally, the C-terminal region present mainly acidic residues and
therefore can modulate the formation of α-synuclein aggregates
depending on the pH of the environment (Hoyer et al., 2002).
PHYSIOLOGICAL ROLE OF α-SYNUCLEIN
The physiological role of α-synuclein has not been determined
with certainty yet, mainly because knockout mice for this protein
do not present a substantial change in the phenotype, suggest-
ing that its function is likely redundant (Chandra et al., 2004).
So far, it has been determined that α-synuclein is expressed after
synaptic development, suggesting that synucleins may not be crit-
ical for synapse formation (Murphy et al., 2000). Mice lacking
α-synuclein were found to show increased release of dopamine
at the striatum, indicating that this protein could function as
an activity dependent negative regulator of neurotransmission
in this brain region (Abeliovich et al., 2000). However, substan-
tial evidence now indicates that α-synuclein is a key regulator
for synaptic vesicle dynamics (Murphy et al., 2000; Chandra
et al., 2004, 2005; Burre et al., 2010). It has been shown that α-
synuclein acts as a nonclassical chaperone (Burre et al., 2010),
complementing the action of CSPα (cysteine-string-protein-α),
whose function is to facilitate the correct assembly of the soluble
N-ethylmaleimide-sensitive factor attachment protein receptor
(SNARE) complex that participates in vesicular release (Chandra
et al., 2005). Another studies demonstrates that the loss of α-,
β-, and γ-synuclein genes results in neuronal dysfunction as the
mice age progresses (Greten-Harrison et al., 2010). Is important
to know that different evidences indicates that presynaptic dys-
function act as an early event of neurodegeneration (Gray et al.,
2009; Nemani et al., 2010), therefore a failure of the maintenance
of SNARE protein function in neurotransmitter release could lead
to PD (Sharma et al., 2012), which could be due to a dysfunction
of α-synuclein (Burre et al., 2010; Greten-Harrison et al., 2010;
Nemani et al., 2010).
PATHOLOGICAL ROLE
Since α-synuclein is a cytosolic protein, it is assumed that the
principal pathological alterations induced by this protein occur
only at the intracellular level. Among the mechanisms that
explain the role of intracellular α-synuclein on PD pathogenesis,
the following are well known: (1) inhibition of the ubiquitin-
proteasome system (Emmanouilidou et al., 2010), (2) changes in
synaptic vesicle release (Murphy et al., 2000), (3) mitochondrial
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dysfunction (Elkon et al., 2002), (4) pore formation (Volles et al.,
2001; Quist et al., 2005), and (5) production of reactive oxygen
species (Junn and Mouradian, 2002). All these alterations would
eventually lead to neuronal dysfunction and death (Cookson and
van der Brug, 2008). However, recent studies have identified the
presence of extracellular α-synuclein (El-Agnaf et al., 2003, 2006),
suggesting that the pathogenic action of this protein may also take
place in the extracellular space (Lee et al., 2008; Lee, 2008; Luk
et al., 2009).
It is possible that α-synuclein has a dual role: a physiolog-
ical role involved in the regulation of synaptic transmission;
and a pathological role associated with neurodegenerative pro-
cesses. Can these two roles be sequentially/temporally/directly
connected? There is still no clear answer to these questions, but
we think that there must be a synaptic switch that commands the
onset of the disease. So it is important to understand what are the
differences and similarities between the pathogenic and physio-
logical mechanisms of α-synuclein. Part of the answer might lay
in the structural flexibility that α-synuclein displays which facili-
tates the transition from a soluble (physiological) to an aggregate
state (pathogenic).
α-SYNUCLEIN AGGREGATES
With respect to the process of α-synuclein aggregation, in vitro
studies indicate the presence of a nucleation-dependent mecha-
nism characterized by a slow onset (Cremades et al., 2012) and
a subsequent growth phase culminating in a steady state (Wood
et al., 1999). This depends on the nature of α-synuclein (wild-type
or mutant) (Li et al., 2001), as well as the incubation conditions
such as pH, temperature (Uversky et al., 2001a), concentration of
metal ions (Uversky et al., 2001b), and other agents such as pes-
ticides (Uversky et al., 2001c). Structurally, the aggregates in vitro
closely resemble aggregates from brain exhibiting typical amyloid
fibril morphology (Conway et al., 2000). New evidence suggests
that wild-type α-synuclein forms a stably folded tetramer that
resists aggregation (Bartels et al., 2011). On the basis of these
recent findings, it has been proposed that destabilization of the
helically folded tetramer precedes α-synuclein misfolding and
aggregation in PD. Mutations associated to PD, both A53T and
A30P, promote the formation of prefibrilar oligomeric species,
while E46K reduces the formation of these aggregates (Bisaglia
et al., 2009). Additionally, potentially toxic species appear to cor-
respond to low molecular weight species such as dimers, trimers,
tetramers, pentamers, and hexamers, which have molecular
weights between 20–100 kDa (Danzer et al., 2007). The mecha-
nism through which α-synuclein monomers are converted into
toxic oligomers and then fibers is largely unknown (Tsigelny et al.,
2007), but it is believed that this process initiates at the plasma
membrane in lipid raft micro domains (Bar-On et al., 2008).
α-SYNUCLEIN SECRETION
How is α-synuclein secreted? Although the exact mechanism has
not been characterized yet, it has been found that a small por-
tion of α-synuclein is secreted into the extracellular medium
via unconventional exocytosis, different to the classical exocyto-
sis through ER/Golgi (Lee et al., 2005), which is expected since
α-synuclein lacks an ER targeting signal peptide (Lee et al., 2005).
The mechanism of the nonconventional exocytosis is not well
understood; therefore it could be more than one mechanism
to explain this new pathway (Nickel and Rabouille, 2009). The
model presented in Figure 2 describes several ways to explain
the secretion of soluble and aggregated forms of α-synuclein.
The α-synuclein secretion would occur under physiological con-
ditions although it would be more prone under pathological
conditions, such as those associated to mitochondrial and pro-
teosomal dysfunction, which are associated with PD (Lee et al.,
2005). It was reported that α-synuclein has a higher aggrega-
tion rate into secretory vesicles compared to cytosolic α-synuclein
(Lee et al., 2005). Two main hypotheses are considered for this
phenomenon: (1) α-synuclein is incorporated within the vesi-
cles by unknown mechanisms. Once the protein is in the vesicles,
it increases the aggregation due to the acidic pH (Hoyer et al.,
2004); or (2) pre-aggregated α-synuclein is translocated to secre-
tory vesicles forming aggregates that are subsequently released
into the extracellular medium, where it could activate a patholog-
ical process. In fact, extracellular α-synuclein aggregates induce
microglial activation, cytokine release, cell death, and plasma
membrane permeabilization (Feng et al., 2010; Van Rooijen et al.,
2010). Moreover, this extracellular α-synuclein could be taken up
through endocytosis to favor the formation of LB-like inclusions
in neighboring cells, which could explain the neuropathological
progression of PD (Desplats et al., 2009).
ROLE OF Ca2+ IN PARKINSON’S DISEASE
Ca2+ has critical roles in neuronal functions, including the reg-
ulation of neurite outgrowth and synaptogenesis, synaptic trans-
mission and plasticity, and cell survival (Mattson, 2007). There is
a lot of evidence indicating the involvement of Ca2+ in PD. Some
studies indicate that α-synuclein controls the function of volt-
age gated calcium channels (Adamczyk and Strosznajder, 2006;
Hettiarachchi et al., 2009), while other studies indicate that this
protein is able to increase the levels of intracellular Ca2+, prob-
ably due to alterations in the membrane, leading to neuronal
death (Danzer et al., 2007). This is consistent with studies in
human neural cells overexpressing mutant α-synuclein, which
have higher plasma membrane ion permeability and basal level
of intracellular Ca2+ compared to control cells (Furukawa et al.,
2006). Interestingly, it was recently found that Aβ aggregates
(implicated in AD) were able to form structures that act as
pore/perforations in the neuronal membranes (Sepulveda et al.,
2010). This action induced an acute increase in intracellular
Ca2+ and a decrease in synaptic proteins in neurons chronically
treated with Aβ aggregates (Parodi et al., 2010; Sepulveda et al.,
2010). Based on the fact that other amyloidogenic proteins like
Aβ can be inserted into the membrane and form perforations
(Sepulveda et al., 2010), this might be one of the mechanism
by which extracellular α-synuclein causes neurodegeneration,
i.e., pore/perforation formation in the plasma membrane lead-
ing to an increase in free intracellular Ca2+ concentration with
subsequent cell death. This idea is supported by another study
showing that cells expressing α-synuclein and treated with Aβ
displayed increased current amplitudes and calcium influx con-
sistent with the formation of cation channels (Tsigelny et al.,
2008a).
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FIGURE 2 | A hypothetical model for secretion and synaptic targets of
α-synuclein oligomers. The figure shows four different mechanisms for
unconventional secretion of α-synuclein (Nickel and Rabouille, 2009).
Mechanism 1 depicts a non-vesicular translocation of α-synuclein mediated
by an unknown transmembrane protein located at the plasma membrane.
Mechanisms 2–4 depict vesicular mechanisms for α-synuclein secretion that
involve lysosomes (2), microvesicle shedding (3), or endosome/multivesicular
bodies (4). Mechanisms 3 and 4 involve the release of α-synuclein into
exosomes. Once in the extracellular space (Lee, 2008), α-synuclein oligomers
can be removed by proteolytic degradation (A) or endocytocis (C) (Desplats
et al., 2009). The accumulation of α-synuclein in the extracellular space can
activate microglia (D) or alter the plasma membrane through the formation of
pore/perforations (B) that can deregulate calcium and metal transition
homeostasis (Danzer et al., 2007).
FORMATION OF α-SYNUCLEIN PORES/PERFORATIONS
One of the first steps in the formation of pores/perforations is the
association of α-synuclein to the membrane, which is discussed
in the following two sections:
α-SYNUCLEIN ASSOCIATION TO MEMBRANES
It has been shown that α-synuclein associates with phospholipid
bilayers in artificial membranes, especially with those membranes
containing acidic phospholipids (Davidson et al., 1998), since the
lipophilic N-terminal region of α-synuclein is positively charged
at physiological pH (Rhoades et al., 2006). Furthermore, this
association could be stabilized by increasing the α-helical sec-
ondary structure of α-synuclein (Davidson et al., 1998; Jo et al.,
2000; Eliezer et al., 2001; Chandra et al., 2003). Another criti-
cal factor for the association of α-synuclein to membranes is the
membrane size. It has been shown that α-synuclein preferentially
associates to vesicles with small diameters (20–25 nm) (Davidson
et al., 1998). On the other hand, recent studies demonstrate that
the interaction of α-synuclein with vesicular membranes is fast
and reversible and the binding of α-synuclein to neutral and
negatively charged membranes occurs by apparently different
mechanisms (Shvadchak et al., 2011).
In natural membranes, α-synuclein has been shown to asso-
ciate, as a peripheral membrane protein, with synaptic vesicles
(Maroteaux et al., 1988), axonal transport vesicles (Jensen et al.,
1998), lipid droplets (Cole et al., 2002), and yeast vesicles (Outeiro
and Lindquist, 2003). It has been demonstrated that α-synuclein
binding occurs at the outer membrane leaflet of the plasmamem-
brane especially in lipid rafts, domains rich in cholesterol, and
sphingolipids (Fortin et al., 2004; Bar-On et al., 2008). These
micro domains are characterized by slow lateral diffusion of the
lipid acyl chains as well as detergent resistance (Allen et al., 2007).
Moreover, lipid rafts are involved in the interaction between lipids
and hydrophobic residues of the amphipathic α-helix present in
the N-terminal of α-synuclein (Tsigelny et al., 2007). Deletion
of the N-terminal residues leads to attenuations of α-synuclein
toxicity toward yeast, suggesting that the toxicity depends on the
N-terminal membrane-binding domain (Vamvaca et al., 2009).
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This was confirmed by point mutations in the N-terminal site of
α-synuclein (A30P, E46K, and A53T) associated with familial PD
(Polymeropoulos et al., 1997; Kruger et al., 1998; Zarranz et al.,
2004).
MODELS OF α-SYNUCLEIN PORES/PERFORATIONS
One of the biggest complications in understanding the structure
of the α-synuclein pore is that there are no crystallographic data
for this protein, likely due to the complexity to crystallize amy-
loid species. There is also a lack of high-resolution models for
biological membranes that would aid in the understanding of the
mechanism by which α-synuclein pores/perforations are formed.
However, there are mainly two types of pore models, toroidal and
barrel (Yang et al., 2001), that may explain α-synuclein perfora-
tion properties (Figure 3). A toroidal model involves a sequential
binding of α-synuclein monomers to lipid membranes that result
in the formation of pores or channels with α-helical confor-
mation (Zakharov et al., 2007). In fact, it is believed that the
basic KXKE repetitions in the N-terminal of α-synuclein act as a
membrane voltage sensor (Zakharov et al., 2007). Furthermore,
in silico studies have shown that the sequential binding of
α-synuclein to the membrane occurs between the N-terminal of
each of the monomers, leading to the formation of pentamers
and hexamers to generate ring-type structures with different
external size ranges (9–15 nm) and internal diameters (2–5 nm)
(Tsigelny et al., 2007). Even aged samples of α-synuclein, with an
FIGURE 3 | Primary and secondary structure of α-synuclein. Top scheme
shows the three main domains of α-synuclein. The N-terminal (red) is an
amphipathic domain that contains the three point mutations (white bars)
linked to the autosomal dominant form of PD (Bisaglia et al., 2009). The
central region (green-pale brown) is a highly hydrophobic domain that was
originally identified in patients with AD or LBD, which is the precursor of the
non amyloidogenic component of the extracellular senile plaque (NAC), which
promotes the protein aggregation (Ueda et al., 1993). The C-terminal domain
(blue) has an acidic character, which possesses anti-amyloidogenic properties
(Hoyer et al., 2004). According to the operational model of membrane
perforation, once α-synuclein interacts with the plasma membrane, it should
acquire a new secondary structure to form pores/perforations. The formation
of α-synuclein pores may be explained by two different models: (A) A toroidal
model involving a sequential binding of α-synuclein monomers to the plasma
membrane that results in the formation of pores or channels with α-helical
conformation (Zakharov et al., 2007); and (B) A barrel model showing that
α-synuclein oligomers (β-sheet-rich) form ring structures with a central pore
(Volles and Lansbury, 2003). The formation of α-synuclein oligomers enriched
in β-sheet structures could occur in the extracellular space (1) or at the
plasma membrane (2).
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expected β-sheet oligomeric conformation, were shown to bind
vesicles in an α-helical state (Smith et al., 2008). This model
contrasts with the barrel model that indicates that α-synuclein
oligomers (β-sheet-rich) form ring structures with a central
pore (Volles and Lansbury, 2003). These aggregates would bind
in the membrane (Volles et al., 2001) causing its permeabi-
lization in a concentration-dependent manner, which has been
shown in liposomes (Volles et al., 2001) and artificial mem-
brane bilayers (Kayed et al., 2004). Moreover, using atomic force
microscopy (AFM), it was found that α-synuclein in artificial
membranes form pores with an outer diameter of 8–10 nm and
an inner diameter of 1–2 nm (Quist et al., 2005). Interestingly,
this type of structure is very similar to the structures formed
by pore forming proteins such as amylin (Quist et al., 2005)
and gramicidin (Diociaiuti et al., 2002). Analysis of single chan-
nel currents in artificial membranes indicated that α-synuclein
aggregates form pores with different conductances, suggesting
that different α-synuclein oligomeric species are involved in the
formation of these membrane structures (Quist et al., 2005).
In addition, studies performed with the α-synuclein mutants,
A53T, and A30P; suggest that PD-associated mutations may affect
the architecture of the α-synuclein pore/perforations (Furukawa
et al., 2006). This pore-like activity may only be associated
with α-synuclein protofibrils, since β-synuclein protofibrils (also
enriched in β-sheet structures) are apparently not able to perme-
ate or bind to lipid vesicles (Park and Lansbury, 2003). These
permeabilizing pore-like structures should only allow the selec-
tive transport of molecules according to the molecular diameter.
For example, both Ca2+ and dopamine pass through the mem-
brane in the presence of α-synuclein protofibrils, while larger
molecules such as cytochrome c do not (Volles et al., 2001).
On the other hand, it has been shown that these pores or per-
forated structures are sensitive to Zn2+ (Tsigelny et al., 2007),
likely as a result of the interaction between Zn2+ and cys-
teine, histidine or arginine residues of α-synuclein. Specifically,
the histidine residue 50 of the α-synuclein monomer is consid-
ered as a possible candidate for interaction with Zn2+, mainly
because it is located near the site of the putative pore (Zakharov
et al., 2007). The above is consistent with studies in human
cells overexpressing mutant α-synuclein whose ionic permeability
is affected by chelation of divalent cations (Furukawa et al.,
2006).
CONCLUSIONS
In conclusion, we reviewed information that supports the role
of extracellular α-synuclein in PD. Like other prone-aggregating
proteins, α-synuclein can interact with lipids in the plasma
membrane, increasing membrane permeability by the forma-
tion of not well characterized structures (pore or perforations)
that may lead to calcium or transition metal dyshomeosta-
sis, which may induce subsequent synaptotoxicity and neuronal
death.
α-Synuclein protein is the main component of LBs present
in PD, DLB, and related neurodegenerative diseases. Therefore,
α-synuclein aggregates (intracellular and extracellular) could be
enhancing the synaptotoxic/neurotoxic effects of other protein
aggregates (oligomers) such as Aβ aggregates. In fact, recent stud-
ies have shown that Aβ and α-synuclein form hybrid pore-like
oligomers that could change membrane permeability (Tsigelny
et al., 2008b).
However, further studies are needed to understand the precise
mechanisms by which extracellular α-synuclein forms channels,
pores, or perforations and the role that these structures have
in neurodegenerative diseases, especially in PD. A crucial ques-
tion is what α-synuclein species are able to disrupt the plasma
membrane? Future experiments should identify these structures
and determine if they are potential targets for pharmacological
therapies.
Currently, we believe that studies focused on unraveling the
mechanism of the formation of α-synuclein pore/perforations
will provide new insights for the generation of innovative
approaches to interfere with these synaptotoxic/neurotoxic pro-
cesses initiated at the neuronal membrane in order to develop
new therapeutic strategies for treating people with PD and other
neurodegenerative diseases.
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